Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 8/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70091 | 1.00 | EPHX2 (0.47) | EPHX2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL83327 | 0.94 | HDAC3 (0.44) | EPHX2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL29385064 | 0.94 | HDAC3 (0.44) | EPHX2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL69468 | 0.94 | HDAC3 (0.44) | EPHX2HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL70177 | 0.94 | HDAC3 (0.43) | EPHX2HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL29382301 | 0.94 | HDAC3 (0.43) | EPHX2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL29382275 | 0.92 | EPHX2 (0.43) | EPHX2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL70018 | 0.92 | EPHX2 (0.43) | EPHX2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL70485 | 0.92 | GPR119 (0.47) | EPHX2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL71519 | 0.91 | EPHX2 (0.43) | EPHX2HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433880-B2 | Methods for the treatment of neurological disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-07 | — | — | US | disclosed |
| EP-3566055-B1 | SCD INHIBITOR FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-12 | — | — | EP | disclosed |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433880-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | EPHX2 1185/4885HDAC3 913/4885HDAC1 1842/4885 |
| US-20220040167-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | EPHX2 1185/4885HDAC3 913/4885HDAC1 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.